Should you take TMG with NMN?

Reviewed 17 sourcesPublished by PepVault

NMN does spend methyl groups, but in trials homocysteine barely moved. What TMG does in people, the cholesterol trade-off, and the blood test that decides it.

Silver-haired man in an orange tee juggles a white football on a park lawn, a picnic basket behind
Last reviewed
Sources
17
Questions
6
Compounds
3

The short answer

Usually not, unless a blood test says so. NMN does cost methyl groups: the body clears spare nicotinamide by methylating it. But in trials, homocysteine barely moved: up 1.7 µmol/L on 3,000 mg of NR a day, and no spike after 1,000 mg of NMN. TMG lowers homocysteine by 1 to 2 µmol/L and, at 4 g a day or more, nudges cholesterol up.

Every number checked at its primary source · · 17 sources · How we research

Evidence: Small human studies of the methyl cost (single-dose and 14- to 30-day trials of nicotinamide, NR and NMN, up to 65 people each, only one with an NMN arm reporting homocysteine); randomized trials and meta-analyses for betaine's homocysteine and cholesterol effects; an FDA drug label for homocystinuria. No published trial has tested TMG with NMN.

Silver-haired man in an orange tee juggles a white football on a park lawn, a picnic basket behind

Does NMN use up your methyl groups?

Yes, some, and you can see it in the blood. NMN (nicotinamide mononucleotide) is a form of vitamin B3 that cells build into NAD+, the coenzyme they use to turn food into energy. When enzymes such as sirtuins and PARPs burn NAD+, they release nicotinamide. The body recycles most of it; the spare is cleared by an enzyme called NNMT, which sticks a methyl group (one carbon with three hydrogens) onto it. The tagged molecule, methylnicotinamide, is broken down to two end products, 2PY and 4PY, and leaves in the urine2.

That methyl group comes from SAMe (S-adenosylmethionine), the body's main methyl donor, the same pool that tags DNA and clears stress hormones such as adrenaline25. Once SAMe gives up its methyl, what is left becomes homocysteine, an amino acid that has to be recycled back to methionine. Two routes do that: one runs on folate and vitamin B12, the other on betaine, which is TMG (trimethylglycine)214. So the idea behind the pairing is plain chemistry: NMN sends methyl groups out, TMG brings them back.

The first step is proven in people. Ten healthy Japanese men took single doses of 100, 250 and 500 mg of NMN, and plasma 2PY and 4PY rose with every step up in dose1. The question that matters is the next one: does that cost show up as higher homocysteine or less methylation?

Animal note: in rats fed nicotinamide at 1 or 4 g per kg of food for 8 weeks, blood betaine fell and liver DNA methylation dropped17. Those are far larger amounts for their body size than a capsule, and the result is in rats, not people.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault keeps NMN and TMG in one protocol, and each can carry its own dose-time reminder, so the weeks between two blood tests are logged rather than remembered.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does NMN or NR raise homocysteine in people?

Plain nicotinamide does, quickly. NR and NMN, at the amounts people take, barely move it. These are the human studies that measured it, as of November 2026:

StudyWho, how longDaily amountHomocysteine and methyl markers
Sun 2012546 adults, one dose, 5 hoursNicotinamide 100 mgHomocysteine up in people with normal blood pressure; betaine, a methyl donor, down in everyone
Christen 2026465 healthy adults, 14 days, open-labelNicotinamide 500 mg; NR 1,000 mg; NMN 1,000 mgAfter a nicotinamide dose, the homocysteine rise (area under the curve) was more than 8 times placebo's; no such spike on NR or NMN. Over the 14 days, levels held slightly higher than placebo on NR and nicotinamide; NMN's difference was not significant
NADPARK, via Gaare 2023229 people with Parkinson disease from a placebo-controlled trial, 30 daysNR 1,000 mgSAMe, its by-product SAH and homocysteine in blood cells and muscle unchanged; DNA methylation unchanged, including in MTHFR gene carriers
NR-SAFE, Berven 2023320 people with Parkinson disease, 4 weeks, placebo-controlledNR 3,000 mgSerum homocysteine +1.66 µmol/L at the last visit; the rise came by day 3 and then held. Placebo unchanged. Whole-blood homocysteine, SAMe and SAH unchanged; whole-blood betaine fell slightly; B12 and folate unchanged
Garg 1999652 people with leg-artery disease, 48 weeksNiacin (nicotinic acid), raised from 100 to 1,000 mg, then the trial doseUp 17% while the dose rose to 1,000 mg; 55% above baseline at 18 weeks

The pattern is consistent. A straight dose of nicotinamide floods the clearance route at once, and homocysteine jumps for a few hours45. NR and NMN reach the body more slowly, and the trial's authors propose that gut bacteria handle part of each first4; the trials found no spike on either, no fall in SAMe and no change in DNA methylation over 30 days234. Even at three times the usual NR amount, the rise was 1.66 µmol/L, and it stopped growing after day 33. Niacin, the high-dose cholesterol drug form of B3, is the case with a large and lasting rise6.

One gap stands out. No trial of NMN alone has published a homocysteine result; the NMN arm of the 14-day head-to-head trial is the only published number4. A 29-day trial of 400 mg of NMN a day in 24 healthy adults, sponsored by Seneque, listed homocysteine as an outcome and was completed in March 2023; as of November 2026 its registry record shows no results16. In that head-to-head trial, NMN looked like NR4.

What does TMG do in people?

TMG lowers homocysteine, reliably and modestly, and at the higher amounts it raises cholesterol. Food already supplies about 0.5 to 2 g of betaine a day, from foods such as beets, spinach, cereals and seafood714. The trials, in healthy adults unless noted:

StudyDaily amount, how longHomocysteineCholesterol
Olthof 200371.5, 3 or 6 g, 6 weeks, 76 adults12%, 15% and 20% lower than placeboNot the endpoint here
Steenge 200386 g, 6 weeks, adults with mildly high homocysteine1.8 µmol/L lower than placeboNot the endpoint here
Schwab 2002116 g, 12 weeks, 42 adults with obesity on a dietLower than controlTotal and LDL cholesterol higher than control
Olthof 2005, 3 trials pooled106 g, 6 weeks, 151 adultsLowered (the trials' aim)LDL +0.36 mmol/L (about 14 mg/dL), triglycerides +0.14 mmol/L; lower amounts raised LDL too, not significantly
McRae 2013, 5 trials94 g or more, 6 to 24 weeks-1.23 µmol/LNot pooled
Zawieja 2021, 6 trials124 g or more, 6 to 24 weeksNot pooledTotal +0.34 mmol/L (about 13 mg/dL); LDL, HDL and triglycerides not significant
Ashtary-Larky 2022, pooled13Various amounts-1.30 µmol/LTotal +14.1 mg/dL, LDL +10.3 mg/dL; a subgroup suggested under 4 g a day lowers homocysteine without the lipid rise

Two findings matter most for the NMN question. The drop is small outside the rare inherited diseases: about 1 to 2 µmol/L, even in adults whose homocysteine was mildly high8913, roughly the size of the rise NR-SAFE saw at 3,000 mg of NR3. And the amount decides the trade: at 6 g, LDL rose within 2 weeks10, while a subgroup analysis in the 2022 pooled review suggested that amounts under 4 g a day lower homocysteine without moving lipids13. The Wageningen team that ran the 6 g trials concluded that folic acid, which lowered homocysteine without touching lipids, remains the preferred way to lower it10.

Commonly reported: nothing felt when TMG is added beside NMN, either way; at multi-gram amounts some notice a mild stomach upset, which matches the drug label's most common effects, nausea and stomach distress14.

What is betaine approved for?

Betaine anhydrous is an FDA-approved drug, Cystadane, for homocystinuria: a group of rare inherited conditions in which homocysteine runs many times above normal. The label, last updated April 27, 2026 on DailyMed, calls it a methylating agent that donates a methyl group to turn homocysteine back into methionine14.

The label's dose for adults and children from age 3 is 6 g a day, given as 3 g twice daily, raised as needed by the homocysteine result; some patients have needed up to 20 g14. It warns that in one type, CBS deficiency, betaine can push methionine higher and brain swelling has been reported, a warning about that disease14. The approval shows how well betaine works where homocysteine is very high. It says nothing about adding TMG to NMN in healthy people, which no published trial has tested.

How do you decide if you need TMG with NMN?

Let a blood test decide, not a ratio. The popular 1:1 NMN-to-TMG rule has no trial behind it; homocysteine is a cheap, routine test, and it answers the question for you. One way to run it:

  1. Get a baseline homocysteine and lipid panel before you start NMN or change the amount.
  2. Keep NMN at one daily amount; the trials that measured methyl markers held the amount steady23.
  3. Retest after 6 to 8 weeks. NR-SAFE's rise had appeared by day 33, and the TMG trials read homocysteine at 6 weeks78.
  4. Compare the number with the last one and with your lab's range, not with a supplement maker's band.
  5. If homocysteine rose, take the result to your clinician, who can look at folate and B12, the other recycling route, alongside it. If you add TMG, retest LDL too, since 4 g or more a day raised cholesterol in trials1213.

PepVault keeps NMN and TMG in one protocol, and each can carry its own dose-time reminder, so the weeks between two blood tests are logged rather than remembered. Set reminders in PepVault

  • If you take a statin or another lipid drug, whether TMG fits is your prescriber's call, since it moves cholesterol the other way12.

In PepVault's bloodwork section, add homocysteine as your own marker beside the built-in total cholesterol and LDL, so each panel is saved with its test date. Log it in PepVault

The first trial built to compare the pair is now running. At Concordia University Chicago, 40 healthy adults aged 60 to 80 are split into two groups: one takes an NMN-with-TMG product, the other NMN alone, each for 4 weeks against a 4-week placebo period in a double-blind crossover trial (each person has both periods). It started in February 2026 and is due to finish in January 202715. Its main outcome is exercise tolerance; blood NAD+ is a secondary outcome, and fasting homocysteine is listed among its other outcomes, so it may give the first homocysteine numbers for NMN with and without TMG.

When to get help A homocysteine result above your lab's range, or numbness, tingling or memory changes, which can come with low B12, is a reason to see your clinician.

Where to read more

  • The library pages: pepvault.app/peptides/nmn, /peptides/tmg-betaine (and its stacks page, /peptides/tmg-betaine/stacks) and /peptides/nicotinamide-riboside, and the longevity hub at pepvault.app/longevity.
  • Which precursor raises NAD+ the most is in our guide NAD+ vs NMN vs NR; what a finger-prick NAD+ number does and does not tell you is in Do NAD+ blood tests mean anything?; the short library comparison is at pepvault.app/peptides/compare/nad-vs-nmn.
  • Study pages: pepvault.app/research/nmn-irie-2020 (the 2PY and 4PY rise) and /research/nad-christen-2026 (the head-to-head trial).
  • Placebo, open-label, crossover trial, randomized controlled trial and meta-analysis are explained at pepvault.app/glossary/placebo, /glossary/open-label, /glossary/crossover-trial, /glossary/randomized-controlled-trial and /glossary/meta-analysis.

Track it in the app

Sources

  1. Irie J et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020. PubMed 31685720
  2. Gaare JJ et al. Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience. 2023. PubMed 36936793
  3. Berven H et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023. PubMed 38016950
  4. Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026. PubMed 41540253
  5. Sun WP et al. Excess nicotinamide inhibits methylation-mediated degradation of catecholamines in normotensives and hypertensives. Hypertens Res. 2012. PubMed 21918528
  6. Garg R et al. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J. 1999. PubMed 10577438
  7. Olthof MR et al. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003. PubMed 14652361
  8. Steenge GR et al. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr. 2003. PubMed 12730412
  9. McRae MP. Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. J Chiropr Med. 2013. PubMed 23997720
  10. Olthof MR et al. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Med. 2005. PubMed 15916468
  11. Schwab U et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002. PubMed 12399266
  12. Zawieja EE et al. Betaine supplementation moderately increases total cholesterol levels: a systematic review and meta-analysis. J Diet Suppl. 2021. PubMed 31809615
  13. Ashtary-Larky D et al. Effects of betaine supplementation on cardiovascular markers: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022. PubMed 33764214
  14. CYSTADANE (betaine anhydrous for oral solution) prescribing information. Recordati Rare Diseases. DailyMed, SPL version 7, Apr 27, 2026. dailymed.nlm.nih.gov
  15. NCT07144527. Nicotinamide mononucleotide supplementation for exercise tolerance improvement in healthy older adults (NMN with TMG vs NMN vs placebo). ClinicalTrials.gov, last updated Oct 7, 2026. clinicaltrials.gov
  16. NCT04910061. Safety and pharmacokinetics of nicotinamide mononucleotide (NMN, 400 mg) over 29 days in healthy adults. Seneque SA. ClinicalTrials.gov, completed Mar 2023, no results posted. clinicaltrials.gov
  17. Li D et al. Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. Br J Nutr. 2013. PubMed 23768418

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo